HS code: 30
To | |
Direction | |
From | |
Period | |
Selection products |
Period | Total |
---|---|
2019 | $1.62 K |
Total: | $1.62 K |
Period | Weight, tons. |
---|---|
2019 | 0.02 |
Total: | 0.02 |
Group product | 2019 | 2019 | Ch. | ∑ (2019-2019) | Ratio |
---|---|---|---|---|---|
06 3001: Glands and other organs for organo-therapeutic uses | --- | --- | --- | --- | 0% |
06 3002: Human blood; animal blood; vaccines, toxins, cultures of micro-organisms and similar products | --- | --- | --- | --- | 0% |
06 3003: Medicaments consisting of two or more constituents, for retail sale | --- | --- | --- | --- | 0% |
06 3004: Medicaments consisting of mixed or unmixed products for retail sale | $1.62 K | $1.62 K | 0% | $1.62 K | 100% |
06 3005: Wadding, gauze, bandages and similar articles | --- | --- | --- | --- | 0% |
06 3006: Pharmaceutical goods specified in note 4 to this chapter | --- | --- | --- | --- | 0% |
Total: | $1.62 K | $1.62 K | $1.62 K |
№ | Country | ∑ (2019-2019) | Ratio |
---|---|---|---|
1 | India | $3.7 M | 61.6% |
2 | United States | $636 K | 10.7% |
3 | Ukraine | $522 K | 8.8% |
4 | Belarus | $480 K | 8.1% |
5 | Israel | $204 K | 3.4% |
6 | United Kingdom | $133 K | 2.2% |
7 | Poland | $126 K | 2.1% |
8 | Kazakhstan | $67.6 K | 1.1% |
9 | China | $43.4 K | 0.7% |
10 | Germany | $33.9 K | 0.6% |
11 | Uzbekistan | $20.6 K | 0.3% |
12 | Armenia | $8.56 K | 0.1% |
13 | Italy | $2.9 K | 0% |
14 | Brazil | $2.56 K | 0% |
15 | Slovenia | $2.3 K | 0% |
16 | Spain | $2.25 K | 0% |
17 | Hungary | $1.62 K | 0% |
18 | Belgium | $1.5 K | 0% |
19 | Austria | $1.11 K | 0% |
20 | France | $996 | 0% |
... | ... | ... | ... |
The total for all countries: | $6 M | 100% |
№ | Region | ∑ (2019-2019) | Ratio |
---|---|---|---|
1 | Moskva | $242 M | 59.3% |
2 | Moskovskaya oblast | $157 M | 38.4% |
3 | Nijegorodskaya oblast | $8.7 M | 2.1% |
4 | Novosibirskaya oblast | $552 K | 0.1% |
5 | Kaliningradskaya oblast | $7.74 K | 0% |
6 | Rostovskaya oblast | $1.62 K | 0% |
7 | Sankt-Peterburg | $666 | 0% |
By all regions: | $408 M | 100% |